Compare WAVE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | ALDX |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 39.2M |
| IPO Year | 2021 | 2014 |
| Metric | WAVE | ALDX |
|---|---|---|
| Price | $4.53 | $0.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.75 | $6.60 |
| AVG Volume (30 Days) | 5.9K | ★ 1.6M |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $360.53 | N/A |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.97 | $0.60 |
| 52 Week High | $10.87 | $5.93 |
| Indicator | WAVE | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 32.37 |
| Support Level | $4.54 | N/A |
| Resistance Level | $5.50 | $1.58 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 46.27 | 25.56 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.